Eli Lilly (LLY 0.86%) and Novo Nordisk (NVO -1.53%) have competed for decades. They're both leaders in the areas of insulin ...

Dr Donald Grant, GP and Senior Clinical Advisor at The Independent Pharmacy said: “Christmas is upon us and for individuals ...

Over 18 months, people taking Zepbound lost more weight on average than those on Wegovy, according to the first head-to-head ...

Novo Nordisk's diabetes drug Ozempic has been linked to a rare and serious eye condition that can cause sudden and ...

Some people are not taking weight-loss medications responsibly, the physician says, and don't realize their full implications ...

NVO's CagriSema target of up to 25% in long-term weight loss is highly promising vs. 15% through Wegovy and 20% through ...

Obesity and body mass index in the U.S. have decreased for the first time in more than a decade.

The U.S. obesity rate declined for the first time in a decade last year, coinciding with the rise of GLP-1 weight-loss ...

Over half of American adults are eligible for semaglutide, but insurance and other barriers make it hard for people to access ...

New research found that some anti-obesity medications such as Wegovy and Zepbound may prompt people to drink less. These ...

Popular GLP-1 medications like semaglutide in Ozempic and Wegovy help people lose weight, but what should patients know about ...

It’s quickly become evident that GLP-1 drugs for diabetes, weight loss, and more are the new wonder drugs—if only people ...